rsv

RSV-IN-1 is an inhibitor of human respiratory syncytical virus (hRSV) and reduced the virus infectivity with IC50 value of 0.11 μM.

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

KIN101 (3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene), an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has antiviral activity against RNA viruses, HCV, and RSV.

RSVL-protein-6 (Compound 19a) is an inhibitor of respiratory syncytial virus (RSV) polymerase, with an IC50 of 13 nM in an SPA primer extension-based enzymatic assay. It is capable of inhibiting RSV replication in HeLa cells.

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.

RSV L-protein-IN-2 (Compound A) is a noncompetitive inhibitor of the RSV polymerase with an IC50 of 4.5 μM and demonstrates antiviral activity against long RSV strains with an EC50 of 1.3 μM [1].

RSV L-protein-IN-3 is an inhibitor of wild-type RSV polymerase with an IC50 of 10.4 μM and an EC50 of 2.1 μM (against RSV) and exhibits lower cytotoxicity than the clinical agent Ribavirin [1].

RSV L-protein-IN-4 (Compound C) is a noncompetitive inhibitor of the RSV polymerase, exhibiting an IC50 of 0.88 μM and demonstrating potent antiviral activity against RSV strains with an EC50 of 0.25 μM [1].

RSV L-protein-IN-5 (Compound E) serves as a potent inhibitor of the Respiratory Syncytial Virus (RSV), with an EC50 value of 0.1 μM. It targets RSV polymerase with an IC50 of 0.66 μM and impedes RSV mRNA synthesis through the inhibition of transcript guanylation. The compound demonstrates moderate cytotoxicity, with a CC50 of 10.7 μM in HEp-2 cells, and effectively reduces viral titers in mouse models of RSV infection [1].

TNM001 is an anti-RSV fully humanized monoclonal antibody for the study of lower respiratory tract disease due to RSV infection.

RSM01 is a fully human IgG1 monoclonal antibody that targets a site in the pre-F region of RSV with a YTE half-life prolongation mutation.

4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde) is an active ingredient of Agastache rugosa.4-Methoxycinnamaldehyde has cytoprotective activity against respiratory syncytial virus (RSV) in human laryngeal carcinoma cell lines, and helps to control disease induced by RSV infection, with an IC50 of approximately 0.055 μg/mL. The IC50 was about 0.055 μg/mL.

Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).

RSV-IN-2 is a powerful compound that acts as a dual inhibitor of both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. It efficiently inhibits the activity of these proteins, with an EC50 value of 0.27 nM for the wild-type and 0.70 nM for the D486N-mutant protein.

RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV), demonstrating anti-RSV activity with an EC50 of 11.76 μM.

RSV-IN-3 (Compound 1) is a dual inhibitor targeting both the respiratory syncytial virus (RSV) and influenza virus A (IAV), with an anti-RSV efficacy demonstrated by an EC50 of 32.70 μM [1].

RSV IAV-IN-2 (compound 14c) is a potent dual inhibitor of RSV IAV, demonstrating lower cytotoxicity than the clinical drug Ribavirin, and shows potential for RSV and or IAV infection research [1].

RSV IAV-IN-1 (compound 14e) is a potent dual inhibitor of RSV IAV, exhibiting lower cytotoxicity than Ribavirin and indicating significant potential for researching RSV and or IAV infections [1].

RSV-IN-6 (Compound 53) is a specific inhibitor of the respiratory syncytial virus (RSV) that targets the M2-1 protein, demonstrating strong potency with EC50 values of 4.4 μM against RSV-A and 1.3 μM against RSV-B strains [1].